S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00134095
Recruitment Status : Unknown
Verified January 2010 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : August 24, 2005
Last Update Posted : September 17, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as S-1 and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may shrink the tumor so that it can be completely removed.

PURPOSE: This phase II trial is studying how well giving S-1 together with irinotecan works in treating patients who are undergoing surgery for locally advanced stomach cancer.

Condition or disease Intervention/treatment Phase
Gastric Cancer Drug: irinotecan hydrochloride Drug: tegafur-gimeracil-oteracil potassium Procedure: adjuvant therapy Procedure: conventional surgery Procedure: neoadjuvant therapy Phase 2

Detailed Description:



  • Determine the efficacy of neoadjuvant S-1 and irinotecan in patients with locally advanced gastric cancer.


  • Determine the histological response in patients treated with this regimen.
  • Determine the overall survival of patients treated with this regimen.
  • Determine the progression-free survival of patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.
  • Determine postoperative morbidity in patients treated with this regimen.
  • Determine the rate of potentially curative surgery in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive oral S-1 on days 1-21 and irinotecan IV over 90 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo gastrectomy with lymphadenectomy. After surgery, patients resume treatment with S-1 alone as before for 1 year.

PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Study of Preoperative S-1/CPT-11 Combination Chemotherapy in Patients With Locally Advanced Gastric Cancer
Study Start Date : September 2004
Actual Primary Completion Date : August 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer

Primary Outcome Measures :
  1. Tumor shrinkage
  2. Historical tumor shrinkage
  3. Overall survival
  4. Progression-free survival
  5. Median survival
  6. Safety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed gastric adenocarcinoma

    • Locally advanced disease

      • Clinical stage T3-4, N0-3, M0 (according to the Japanese gastric cancer classification)
  • Planning to undergo curative surgery after neoadjuvant chemotherapy



  • 20 to 75

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • WBC 4,000-12,000/mm^3
  • Granulocyte count ≥ 2,000/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL


  • AST and ALT ≤ 100 U/L
  • Bilirubin ≤ 1.5 mg/dL


  • Creatinine normal OR
  • Creatinine clearance ≥ 50 mL/min


  • PaO_2 > 60 mm Hg on room air


  • Able to swallow oral medication


Biologic therapy

  • No prior biologic therapy for gastric cancer


  • No prior chemotherapy for gastric cancer

Endocrine therapy

  • No prior endocrine therapy for gastric cancer


  • No prior radiotherapy for gastric cancer


  • No prior surgery for gastric cancer


  • No other prior therapy for gastric cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00134095

Yamamoto Kumiai General Hospital
Noshiro, Akita, Japan, 016-0014
Asahikawa Kosei General Hospital
Asahikawa, Hokkaido, Japan, 078-8211
Kobe City General Hospital
Kobe, Hyogo, Japan, 650
Iwate Medical University Hospital
Morioka, Iwate, Japan, 020-8505
Tsuruoka Municipal Shonai Hospital
Tsuruoka, Yamagata, Japan, 997-8515
Fukushima Medical University Hospital
Fukushima, Japan, 960-1295
Yamagata Prefectural Central Hospital
Yamagata, Japan, 990-2292
Sponsors and Collaborators
Fukushima Medical University Hospital
Study Chair: Mitsukazu Gotoh, MD Fukushima Medical University Hospital Identifier: NCT00134095     History of Changes
Other Study ID Numbers: CDR0000439474
First Posted: August 24, 2005    Key Record Dates
Last Update Posted: September 17, 2013
Last Verified: January 2010

Keywords provided by National Cancer Institute (NCI):
adenocarcinoma of the stomach
stage II gastric cancer
stage III gastric cancer
stage IV gastric cancer

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic